Dissolution Testing in Pharma - From Development to Regulatory Approval
About the Course
Dissolution testing plays a central role in demonstrating pharmaceutical product performance, supporting bioavailability assessment, formulation development, and ongoing quality control. Weak or inconsistent dissolution practices can create significant compliance and manufacturing concerns, including batch failures, regulatory observations, and product recalls. Regulatory expectations from FDA, USP, and ICH place increased emphasis on scientifically justified methods, reliable apparatus qualification, and consistent execution throughout the product life cycle.
The course addresses the scientific and operational factors that influence dissolution behavior, including particle size, solubility, pKa, diffusion models, excipient selection, and manufacturing conditions. Attention is also given to apparatus selection, calibration practices, discriminating method development, IVIVC evaluation, validation activities, and troubleshooting approaches linked to FDA 483 findings. These areas directly affect data reliability, submission quality, and confidence in batch-to-batch consistency during development and commercial production. The material supports phase-appropriate decision making across formulation, analytical, quality, and regulatory functions.
Key Areas Covered
Quality training, expert insights, and answers that matter. Know your Expert
Commonly Asked Questions About This Subject
How do regulators determine whether a dissolution method is scientifically justified rather than simply suitable for routine testing?
A dissolution method is considered scientifically justified when the supporting evidence demonstrates that it can distinguish meaningful changes in product performance while remaining appropriate for its intended purpose. Regulators look beyond successful test execution and examine why the selected conditions provide reliable and relevant information.
Inspection discussions often shift toward the decisions made during method development rather than the final method itself. Reviewers may question the rationale for medium selection, agitation speed, sampling times, acceptance criteria, or any modifications introduced during development if the supporting evidence is incomplete.
Development teams sometimes focus on obtaining consistent results while giving less attention to documenting why the method represents product behavior. Consistency alone does not demonstrate that the method can detect changes that matter from a quality or performance perspective.
A defensible method is supported by documented scientific reasoning, comparative development data, and evidence that critical decisions were evaluated before the method was finalized. Those records provide greater confidence than a successful validation report by
When should unexpected dissolution results trigger a broader manufacturing investigation instead of a laboratory investigation?
Unexpected dissolution results should prompt a broader manufacturing investigation when available evidence suggests the laboratory performed the method correctly and the results may reflect changes in the product rather than analytical execution. Confirming analytical performance is only the first step in determining the appropriate scope of investigation.
A recurring inspection concern arises when investigations remain focused on laboratory activities despite indications that formulation, granulation, compression, coating, or other manufacturing variables may have influenced product performance. Reviewers often examine whether all reasonable sources of variability were evaluated before conclusions were reached.
Limiting the investigation should be supported by objective evidence rather than assumptions about where the problem originated. Manufacturing records, process trends, equipment history, raw material variability, and prior batch performance frequently provide important context for the final decision.
Well supported investigations explain why the selected scope was appropriate and how alternative causes were evaluated. That approach demonstrates disciplined decision making and reduces questions about whether significant manufacturing issues were overlooked.
How much historical dissolution data should be evaluated after identifying an unexplained trend or outlier?
The amount of historical data reviewed should be determined by the potential impact of the observation rather than by a predefined time period. Once an unexplained trend suggests that product performance may have changed, reviewers expect the investigation to consider whether similar patterns existed in earlier batches or related products.
Inspection concerns often arise when historical reviews stop at the first acceptable explanation without examining whether the issue developed gradually over time. Trend evaluations that overlook process changes, equipment maintenance, supplier variability, or analytical shifts may provide an incomplete understanding of the underlying cause.
Expanding a historical review does not require examining every available record. The rationale for selecting the review period should be documented and supported by product knowledge, manufacturing history, and risk to product quality.
A well justified historical assessment demonstrates that the investigation boundaries were established using objective evidence. Clear reasoning for including or excluding specific batches strengthens confidence that the conclusions reflect the actual performance history rather than a limited snapshot.
What makes dissolution-related decisions difficult to defend during an FDA inspection?
Dissolution decisions become difficult to defend when the records explain what was done but not why it was done. Inspectors often focus on the scientific reasoning behind method changes, specification decisions, investigation conclusions, and acceptance of atypical results rather than on the existence of documentation alone.
Documentation frequently becomes vulnerable when technical judgments rely on previous practice, internal preference, or undocumented experience instead of objective evidence. Statements that a method has always performed well carry little weight if they are not supported by development data or documented evaluation.
Laboratory records, investigation reports, change controls, validation documents, and manufacturing information should present a consistent technical narrative. Conflicting explanations across these records often create more concern than an individual analytical issue because they raise questions about the reliability of decision making.
Strong documentation allows an independent reviewer to understand the evidence, follow the reasoning, and reach the same conclusion without relying on verbal explanations. That level of transparency separates controlled scientific decisions from conclusions that are difficult to justify during regulatory review.
Ready to Strengthen Your Team? Let’s Build Your Training Plan.
Your team deserves the clarity.
Your organization deserves the confidence.
Upcoming Courses
Your TalkFDA Webinar Experience
1. Confirmation
3. Access course materials
4. Watch The Streaming and Complete your Course


